ABSTRACT
Objective: To study the distribution of levofloxacin in the serum and ascites in patients with cirrhosis and to evaluate its efficacy in treatment of patients with spontaneous bacterial peritonitis(SBP). Methods:（1）Concentration of levofloxacin in the serum and ascites was detected with HPLC in 7 patients with cirrhosis at different time (in the serum: 0.5, 1, 1.5, 2 and 12 h;in the ascites:2, 4, 6 and 12 h). （2）The effects of levofloxacin were observed in treatment of 30 patients with SBP. Results:（1） Levofloxacin was determined in serum and ascites of patients with cirrhosis, whose concentration depended on the duration after oral administration. In serum: tmax was 1.5 h and cmax was (3.913±1.388) μg/ml. In ascites: tmax was 6.0 h and cmax was (2.520±1.213) μg/ml. The levels decreased gradually after reaching peak concentration, then stabilized from 12 h.（2）The symptoms and signs were significantly improved in patients with SBP treated with the levofloxacin. Conclusion: After the oral administration, levofloxacin can both distribute in serum and ascites, and it is efficient in the treatment of the patients with SBP.
ABSTRACT
To study the effect of heparin on the ConA induced acute liver injury inKunming mice,twenty four mice were randomly divided into groups A,B and C.To the mice in group A, 0 2ml of normal saline (NS) was intravenously administered, while those in group B were given ConA 18mg/kg instead of NS in order to induce severe acute liver injury. Heparin was injected subcutaneously in a dose of 100U per animal at the same time as ConA challenge in group C. Compared with group B, prior injection of heparin in group C significantly decreased the mice death rate and the peak levels of serum ALT within 8h. At the same time, intrasinusoidal congestion and hepatic inflammation were alleviated significantly,and MDA level in liver homogenate was lowered markedly. It suggested that heparin is efficient in protecting the mice from liver injury induced by ConA.
ABSTRACT
0.05). The positivity rate of anti-HCV in patients with liver cirrhosis was 7.1%.